[An experimental study of possibility of treatment of hemorrhagic fever Marburg by Remicade].
The effect of Remicade, administered according to different schemes, produced on the course of experimental Marburg hemorrhagic fever was studied. When the drug was used from the first infection day, the treated animals died reliably earlier versus the controls (infected animals). A reliably lower concentration of TNF-alpha in blood serum (versus the controls) was registered on day 3. At the same time, when Remicade was used from day 3 after infection, a 50% survival of animals was registered. It is noteworthy, that the TNF-alpha concentration in blood serum did not differ, on day 3, from that of controls, whereas, beginning from day 5 after infection, the animals displayed a downtrend of TNF-alpha concentration. Hence, it can be an evidence of a dual TNF-alpha role in the immunopathogenesis of Marburg hemorrhagic fever: on day 1 after infection the production of TNF-alpha is needed; whereas, if there is an overproduction of the cytokine, it is necessary to inhibit it. The treatment scheme in hemorrhagic fever must, apparently, comprise both elements of cytokine therapy and drugs affecting other chains of pathogenesis--they must mainly protect the endothelial vascular cells.
Ignat'ev
G M
GM
Bukin
E K
EK
Otrashevskaia
E V
EV
D000818:Animals; D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D018501:Antirheumatic Agents / Q000627:therapeutic use*; D006168:Guinea Pigs; D000069285:Infliximab; D008379:Marburg Virus Disease / Q000188:drug therapy*; D016896:Treatment Outcome
D000911:Antibodies, Monoclonal; D018501:Antirheumatic Agents; D000069285:Infliximab